Skip to content
Screener

Ionis Pharmaceuticals IONS Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
$269M+399%
Arrowhead Research logo
Arrowhead ResearchARWR
$3.7M+132%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$18.99M+18.5%
ALN
Alnylam PharmaceuticalsALNY
-$53.64M-180%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.42M+17.1%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Interest expense(4,618)(4,114)(9,778)(8,223)
Interest expense related to sale of future royalties(17,506)(18,648)(34,843)(37,470)
Gain (loss) on investments, net(10,182)(18,312)12,401(20,476)
Other income, net987102529569
Income (loss) before income tax benefit (expense)(113,382)123,531(205,692)(23,291)
Income tax benefit (expense)(1,264)20(1,482)(96)
Net income (loss)$$(114,646)$123,551$(207,174)(23,387)
Basic net income (loss) per share$$(0.69)$0.78$(1.25)(0.15)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's other income (expense)?
Ionis Pharmaceuticals (IONS) reported other income (expense) of $987K in Q2 2026.
How has Ionis Pharmaceuticals's other income (expense) changed year-over-year?
Ionis Pharmaceuticals's other income (expense) increased by 867.6% year-over-year, from $102K to $987K.
What is the long-term trend for Ionis Pharmaceuticals's other income (expense)?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's other income (expense) has grown at a 91.9% compound annual growth rate (CAGR), from -$1.13M to -$15.36M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Ionis Pharmaceuticals's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude